- Home
- MCO vs BMY Comparison
MCO vs BMY Comparison
Compare MCO & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCO | BMY |
|---|---|---|
| Founded | 1900 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2B | 113.5B |
| IPO Year | 1998 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MCO | BMY |
|---|---|---|
| Price | $513.12 | $67.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 15 |
| Target Price | ★ $543.75 | $61.73 |
| AVG Volume (30 Days) | 707.7K | ★ 11.6M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | 0.90% | ★ 4.38% |
| EPS Growth | 21.40 | ★ 178.46 |
| EPS | ★ 8.75 | 2.93 |
| Revenue | $4,204,100,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $58.46 | ★ $22.96 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $402.28 | $42.52 |
| 52 Week High | $546.88 | $68.64 |
Technical Indicators
Market Signals| Indicator | MCO | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.68 | 64.35 |
| Support Level | $496.59 | $56.46 |
| Resistance Level | $523.31 | $68.10 |
| Average True Range (ATR) | 10.13 | 1.43 |
| MACD | 2.64 | 0.07 |
| Stochastic Oscillator | 81.71 | 77.93 |
Price Performance
Historical ComparisonAbout MCO Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.